Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Gtree
Biotech company acquires OMRF brain cancer drug
Agreement will expand clinical trials of glioblastoma drug
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Agreement will expand clinical trials of glioblastoma drug